Acute Myeloid Leukemia (AML) Medical Education Grant
Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.
- The role of intensive chemotherapy in the treatment of high-risk AML
- Timely diagnosis and treatment initiation in high-risk AML subgroups (eg, AML-MRC, tAML)
- Different technologies for the delivery of high-risk AML treatments
- Depth of response, real world data and long-term outcomes
- Appropriate management of high-risk AML in the inpatient and outpatient settings
- The AML treatment paradigm (eg, induction, consolidation, combination therapy, maintenance therapy) and patient management
- Clinical and economic burden of high-risk AML
- Evidence-based managed care considerations for AML therapies
Jazz Pharmaceuticals (JAZZ) is committed to advancing scientific knowledge and clinical expertise within the medical and scientific communities with the ultimate goal of improving patient care.
This site allows you to submit Independent Medical Education (IME) requests for US and Ex-US activities or initiatives that serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of healthcare professionals (e.g., continuing medical education, continuing health education, continuing education).
IME is supported education (accredited or non-accredited) in which JAZZ exercises no control, influence, or direction over any aspect of the program, including but not limited to educational design, faculty, authors, speakers, etc. All grants must comply with local regulations.
We are currently accepting requests for:
- Meetings, Conferences, or Symposia
- Medical Center Grand Rounds lectures
- Fellowships
- Enduring IME activities, which may include strategies, tools, and other educational resources to use with patients
- Patient education in conjunction with Health Care Provider (HCP) education
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.